Study of an Indian public-listed company
Final Project Report
Products and Services
The Auditors report
The Director’s Report
Cash flow analysis
Established in 1978, Biocon is India's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to 'Develop novel & affordable Biotherapeutics for global markets'. Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction. The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon's products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents, hepatoprotective agents, immunosuppressants, nutraceuticals and orthopaedic agents. With its strong focus on R&D Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials. Biocon Park, inaugurated in June 2006 by President APJ Abdul Kalam comprises an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Bommasandra Industrial Area – Phase IV. Built with a total investment of Rs. 650 crores, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 30-year history and is focused on exports of both bio-pharmaceutical products and research services. The multi-product facilities mainly cater to the following disease segments: cardiovascular, cholesterol reduction, immunosuppressants in organ transplantation, diabetes and cancer. Biocon's success has been characterized by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India's first and leading biotechnology company Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India. Biocon aims to continuously create growth in different areas of the company and is the first company, globally to manufacture human insulin, Insugen® using a Pichia expression system. In addition, in 2006, Biocon launched BIOMAb EGFR™, the first indigenously developed humanized monoclonal antibody for Head & Neck cancer.
Syngene International Limited is a custom research organisation offering synthetic chemistry and molecular biology services...
Please join StudyMode to read the full document